Egyptian GH deficient patients: demographic, auxologixcal characterization and response to GH therapy

Nermin Salah; Soha Abd El Dayem; Mogy Fatma El; Lobna Fawaz; Marwa Ibrahim

doi:10.1530/endoabs.32.P819

P819

Prev Next

Section Contents Cite

Endocrine Abstracts (2013) 32 P819 | DOI: 10.1530/endoabs.32.P819

ECE2013 Poster Presentations Paediatric endocrinology (32 abstracts)

Egyptian GH deficient patients: demographic, auxologixcal characterization and response to GH therapy

Nermin Salah ¹ , Soha Abd El Dayem ² , Fatma El Mogy ³ , Lobna Fawaz ¹ & Marwa Ibrahim ¹

Err

Author affiliations

¹Pediatrics Department, Faculty of medicine, Cairo University, Cairo, Egypt; ²Pediatrics Department, National Research Centre, Cairo, Egypt; ³Clinical Pathology Department, Faculty of medicine, Cairo University, Cairo, Egypt.

Objective: To study the growth response to GH treatment in GH deficient patients. Also to report the possible side effects emerging during treatment with GH.

Patients and methods: 477 GH deficient (GHD) children were included in the study. All patients received biosynthetic GH therapy at a dose of 20 IU/m² per week. Patients were followed up for a minimum of 1 year and up to 6 years as anthropometric assessment was performed every 3 months, while thyroid profile was followed every 6 months. Student’s t-test was used for analysis of two quantitative variables.

Results: Patients with complete GHD and multiple pituitary hormone deficiency (MPHD) were significantly shorter as expressed in their height SDS, target height–height (SDS) and a more bone age delay (P<0.05). Patients with complete GHD showed better growth response compared to those with partial GHD in the first 2 years of therapy.

Conclusion: We conclude that anthropometric assessment is the corner stone in GHD diagnosis and follow up, where catch up growth occurs in the first 2 years of therapy followed by a plateau. GH therapy is generally safe.